Month in Review: Top 10 Articles From August 2023

GSK’s RSV Vaccine Now Available in Some US Pharmacies: What You Need to Know

A Q&A with Marc Ost, co-owner of Eric’s RX Shoppe, which was one of the first community pharmacies to receive the new vaccine.

Read More

FDA Delays Drug Supply Chain Security Act Deadline Until November 2024

The new deadline to be in compliance with the requirements will be November 27, 2024.

Read More

Moderna, Novavax Update Vaccines as COVID-19 Variants Cause Rise in Cases

The CDC and WHO are currently tracking several variants that are driving the majority of new cases around the world.

Read More

Chikungunya Vaccine for Adolescents Shows Positive Topline Results in Phase 3 Trial

PXVX0317 has received Fast Track and Breakthrough Therapy designation from the FDA.

Read More

Chronic Pain Prevalence High Among Women With HIV

Chronic pain is among the comorbidities for people diagnosed with HIV, but there has been a lack of data on the prevalence and risk factors in women.

Read More

Upcoming DIR Fee Changes Still Causing Concern for Pharmacists

New DIR fee rules eliminate clawbacks, but may create cashflow challenges for pharmacies in the first half of 2024.

Read More

Comparing Safety, Efficacy of COVID-19 mRNA Vaccines in Older Adults

Moderna’s mRNA-1273 vaccine was associated with a lower risk of diagnosed COVID-19 when compared to Pfizer’s BNT162b2.

Read More

FDA Gives 510(k) Clearance to COVID-19, Influenza A/B, RSV Combination Test

A 510(k) clearance, or a Premarket Notification, requires device manufacturers to notify the FDA at least 90 days ahead of registration with their intent to market a medical device.

Read More

What You Need to Know About the Drug Supply Chain Security Act Before November’s Deadline

A Q&A with Matt Sample, senior vice president of manufacturer and replenishment operations at AmerisourceBergen.

Read More

COPD Exacerbations Common in Patients Not Treated With Controller Medications

A study found that although the number of patients receiving a controller medication increased after their first exacerbation, the percentage given controller medications remained below 50% among the overall population.

Read More